Literature DB >> 19484231

Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as CYP2C9*3*3.

Tobias Bäckström, Gunilla Barkman, Jonatan D Lindh, Erik Eliasson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19484231     DOI： 10.1007/s00228-009-0670-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Authors:  T H Sullivan-Klose; B I Ghanayem; D A Bell; Z Y Zhang; L S Kaminsky; G M Shenfield; J O Miners; D J Birkett; J A Goldstein
Journal:  Pharmacogenetics       Date:  1996-08

2.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Authors:  A E Rettie; L C Wienkers; F J Gonzalez; W F Trager; K R Korzekwa
Journal:  Pharmacogenetics       Date:  1994-02

3.  Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.

Authors:  H Takahashi; T Kashima; S Nomoto; K Iwade; H Tainaka; T Shimizu; Y Nomizo; N Muramoto; S Kimura; H Echizen
Journal:  Pharmacogenetics       Date:  1998-10

4.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

Authors:  Maria Gabriella Scordo; Vittorio Pengo; Edoardo Spina; Marja Liisa Dahl; Milena Gusella; Roberto Padrini
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

Review 5.  Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.

Authors:  Jonatan D Lindh; Lennart Holm; Marine L Andersson; Anders Rane
Journal:  Eur J Clin Pharmacol       Date:  2008-11-25       Impact factor: 2.953
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.